Luminopia’s digital therapy for lazy eye aces clinical trialA digital therapeutic (DTx) for amblyopia – sometimes known as lazy eye – has been shown to improve Share XLuminopia’s digital therapy for lazy eye aces clinical trialhttps://pharmaphorum.com/news/luminopias-digital-therapy-for-lazy-eye-aces-clinical-trial/
Vectura investors ignore critics and back tobacco giant takeoverTobacco giant Philip Morris International (PMI) has won the shareholder vote it needed for its controversial £1.1 billion Share XVectura investors ignore critics and back tobacco giant takeoverhttps://pharmaphorum.com/news/vectura-investors-ignore-critics-and-back-tobacco-giant-takeover/
Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalTakeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, Share XTakeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalhttps://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/
NICE backs BioCryst’s Orladeyo for hereditary angioedemaBioCryst Pharma’s Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) Share XNICE backs BioCryst’s Orladeyo for hereditary angioedemahttps://pharmaphorum.com/news/nice-backs-biocrysts-orladeyo-for-hereditary-angioedema/
Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dipsPfizer and Moderna have both reported data that they say backs up the need for booster shots of Share XAhead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dipshttps://pharmaphorum.com/news/ahead-of-fda-adcomm-pfizer-moderna-say-covid-jab-efficacy-dips/
Amylyx preps filing for its ALS drug after FDA feedbackJust a few months ago, Amylyx was talking about having to complete another clinical trial before it could Share XAmylyx preps filing for its ALS drug after FDA feedbackhttps://pharmaphorum.com/news/amylyx-preps-filing-for-its-als-drug-after-fda-feedback/
AI aims to prevent unneeded treatment for deep vein thrombosisResearchers in the UK are working on an artificial intelligence (AI) algorithm to help diagnose deep vein thrombosis Share XAI aims to prevent unneeded treatment for deep vein thrombosishttps://pharmaphorum.com/news/ai-aims-to-prevent-unneeded-treatment-for-deep-vein-thrombosis/
Theravance axes staff as lead pipeline drug flunks phase 3 trialTheravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in Share XTheravance axes staff as lead pipeline drug flunks phase 3 trialhttps://pharmaphorum.com/news/theravance-axes-staff-as-lead-pipeline-drug-flunks-phase-3-trial/
ObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantSwiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in Share XObsEva files uterine fibroid drug in US, chasing AbbVie, Myovanthttps://pharmaphorum.com/news/obseva-filed-uterine-fibroid-drug-in-us-chasing-abbvie-myovant/
